Medexus Pharmaceuticals Statistics

Total Valuation

Medexus Pharmaceuticals has a market cap or net worth of 44.51 million. The enterprise value is 104.80 million.

Market Cap	44.51M
Enterprise Value	104.80M

Important Dates

The next estimated earnings date is Tuesday, August 6, 2024.

Earnings Date	Aug 6, 2024
Ex-Dividend Date	n/a

Share Statistics

Medexus Pharmaceuticals has 24.46 million shares outstanding. The number of shares has increased by 20.68% in one year.

Shares Outstanding	24.46M
Shares Change (YoY)	+20.68%
Shares Change (QoQ)	+18.35%
Owned by Insiders (%)	8.69%
Owned by Institutions (%)	8.39%
Float	22.08M

Valuation Ratios

The trailing PE ratio is 4.55 and the forward PE ratio is 14.53.

PE Ratio	4.55
Forward PE	14.53
PS Ratio	0.28
PB Ratio	1.10
P/FCF Ratio	1.57
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.11, with an EV/FCF ratio of 3.69.

EV / Earnings	13.03
EV / Sales	0.66
EV / EBITDA	4.11
EV / EBIT	5.99
EV / FCF	3.69

Financial Position

The company has a current ratio of 1.11, with a Debt / Equity ratio of 1.77.

Current Ratio	1.11
Quick Ratio	0.46
Debt / Equity	1.77
Debt / EBITDA	2.81
Debt / FCF	2.52
Interest Coverage	1.19

Financial Efficiency

Return on equity (ROE) is 19.89% and return on invested capital (ROIC) is 15.51%.

Return on Equity (ROE)	19.89%
Return on Assets (ROA)	3.67%
Return on Capital (ROIC)	15.51%
Revenue Per Employee	1.93M
Profits Per Employee	98,086
Employee Count	82
Asset Turnover	0.71
Inventory Turnover	3.18

Taxes

Income Tax	-9.24M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -13.68% in the last 52 weeks. The beta is 1.89, so Medexus Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	1.89
52-Week Price Change	-13.68%
50-Day Moving Average	1.68
200-Day Moving Average	1.98
Relative Strength Index (RSI)	65.55
Average Volume (20 Days)	48,684

Short Selling Information

The latest short interest is 136,766, so 0.56% of the outstanding shares have been sold short.

Short Interest	136,766
Short Previous Month	121,774
Short % of Shares Out	0.56%
Short % of Float	0.62%
Short Ratio (days to cover)	2.84

Income Statement

In the last 12 months, Medexus Pharmaceuticals had revenue of 158.30 million and earned 8.04 million in profits. Earnings per share was 0.40.

Revenue	158.30M
Gross Profit	83.75M
Operating Income	17.37M
Pretax Income	-1.19M
Net Income	8.04M
EBITDA	25.49M
EBIT	17.49M
Earnings Per Share (EPS)	0.40

Full Income Statement

Balance Sheet

The company has 11.23 million in cash and 71.52 million in debt, giving a net cash position of -60.29 million or -2.46 per share.

Cash & Cash Equivalents	11.23M
Total Debt	71.52M
Net Cash	-60.29M
Net Cash Per Share	-2.46
Equity (Book Value)	40.44M
Book Value Per Share	1.65
Working Capital	10.40M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 28.68 million and capital expenditures -299,562, giving a free cash flow of 28.38 million.

Operating Cash Flow	28.68M
Capital Expenditures	-299,562
Free Cash Flow	28.38M
FCF Per Share	1.17

Full Cash Flow Statement

Margins

Gross margin is 52.91%, with operating and profit margins of 10.97% and 5.08%.

Gross Margin	52.91%
Operating Margin	10.97%
Pretax Margin	-0.75%
Profit Margin	5.08%
EBITDA Margin	16.10%
EBIT Margin	11.05%
FCF Margin	17.93%

Dividends & Yields

Medexus Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.68%
Shareholder Yield	-20.68%
Earnings Yield	18.07%
FCF Yield	63.76%

Analyst Forecast

Price Target	2.94
Price Target Difference	61.54%
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on December 19, 2018. It was a reverse split with a ratio of 1:15.

Last Split Date	Dec 19, 2018
Split Type	Reverse
Split Ratio	1:15